Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 15.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,476 shares of the specialty pharmaceutical company’s stock after purchasing an additional 325 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Jazz Pharmaceuticals were worth $275,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. First Trust Direct Indexing L.P. lifted its holdings in shares of Jazz Pharmaceuticals by 54.1% during the 1st quarter. First Trust Direct Indexing L.P. now owns 2,740 shares of the specialty pharmaceutical company’s stock valued at $330,000 after acquiring an additional 962 shares in the last quarter. Private Advisor Group LLC lifted its stake in shares of Jazz Pharmaceuticals by 6.5% during the first quarter. Private Advisor Group LLC now owns 3,159 shares of the specialty pharmaceutical company’s stock worth $380,000 after purchasing an additional 192 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in shares of Jazz Pharmaceuticals by 45.1% in the first quarter. Janney Montgomery Scott LLC now owns 15,888 shares of the specialty pharmaceutical company’s stock worth $1,913,000 after buying an additional 4,939 shares during the period. Daiwa Securities Group Inc. grew its stake in shares of Jazz Pharmaceuticals by 18.7% in the first quarter. Daiwa Securities Group Inc. now owns 5,586 shares of the specialty pharmaceutical company’s stock valued at $673,000 after buying an additional 879 shares in the last quarter. Finally, Financial Counselors Inc. raised its holdings in shares of Jazz Pharmaceuticals by 28.2% during the 1st quarter. Financial Counselors Inc. now owns 2,376 shares of the specialty pharmaceutical company’s stock valued at $286,000 after buying an additional 522 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on JAZZ. HC Wainwright restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Royal Bank of Canada lifted their price target on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 23rd. Robert W. Baird cut their price target on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. Finally, Morgan Stanley lowered their price objective on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research note on Friday, July 12th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $173.43.

Jazz Pharmaceuticals Trading Up 0.4 %

Shares of NASDAQ JAZZ opened at $110.45 on Monday. The company has a market cap of $6.82 billion, a price-to-earnings ratio of 18.98, a price-to-earnings-growth ratio of 1.38 and a beta of 0.57. The stock’s 50 day simple moving average is $110.68 and its 200 day simple moving average is $109.59. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.48.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.